Navigation Links
Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences
Date:4/23/2012

WASHINGTON, April 23, 2012 /PRNewswire/ --  Covington & Burling represented AstraZeneca in its $1.26 billion acquisition of Ardea Biosciences.  Under the agreement, AstraZeneca will pay $32 per share for all of the outstanding shares of Ardea. 

(Logo: http://photos.prnewswire.com/prnh/20120423/CL92331LOGO )

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. Ardea is a biotechnology company based in San Diego, California, focused on the development of small-molecule therapeutics for the treatment of serious diseases. 

The Covington team was led by Catherine Dargan, with assistance from Stephen Infante and Michael Riella. The team also included John Hurvitz, Emily Leonard, Ashley Nelson, Darien Capron, Brianna Sandoval, Christina Chung, Larry Bartenev and Caitlin Cottingham (life sciences/corporate), Robert Heller and Sarah Burnham (tax), Michael Francese and Katherine Mineka (benefits), Marialuisa Gallozzi and Scott Levitt (insurance), Andrea Reister and Marie Lavalleye (intellectual property), Michael Labson (regulatory), and Deborah Garza, James Dean and Jonathan Herczeg (antitrust). 

Covington & Burling LLP, an international law firm, provides corporate, litigation, and regulatory expertise to enable clients to achieve their goals.  Founded in 1919, the firm has more than 800 lawyers and offices in Beijing, Brussels, London, New York, San Diego, San Francisco, Silicon Valley, and Washington, DC.

Contact

Rebecca Carr


202.662.5110


rcarr@cov.com


'/>"/>
SOURCE Covington & Burling
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. nanoTox COO Greg King Advises Nanotech Companies to View Safety Concerns as an Opportunity to Gain Consumer Trust
2. KTA Capital Advises SpringTree Global Investors on an AU$25.5 Million Investment in Prima BioMed Ltd
3. Jina Ventures Advises Swiss Pharma Contract on Strategic Sale to Covance Inc
4. CV Therapeutics Advises Stockholders to Take No Action at This Time in Response to Astellas Tender Offer
5. Palatin Announces Commencement of a Phase 1 Trial for Obesity Compound in Collaboration with AstraZeneca
6. AstraZeneca and Sarah Cannon Research Institute Join Efforts to Fight Cancer
7. Combined Sales of Seven Emerging Therapies for Breast Cancer, Including Drugs From Sanofi-Aventis and AstraZeneca, Will Total Nearly $5 Billion by 2019
8. Rigel Earns Milestone Payments From AstraZeneca
9. TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis
10. AstraZeneca Outlines Principles for Product-Related Online Communications
11. AstraZeneca CEO Interviewed on Q4 and Full-Year Results 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... , February 16, 2017 ... the infusion of innovative telemedicine application, new and ... that are experiencing a boom worldwide. The healthcare ... advancement of technologies, services and new therapies for ... RQHTF) (TSX-V: RHT), Cellectar Biosciences, Inc. (NASDAQ: ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)...  Rhythm, a biopharmaceutical company developing peptide ... in life-threatening metabolic disorders, today announced the ... of financing with existing investors including Deerfield ... Associates, Pfizer Venture Investments, Third Rock Ventures, ... Rhythm will use the proceeds to advance ...
(Date:2/15/2017)... ... 2017 , ... Executive search firm, Slone Partners, announces the ... Matt is a veteran life sciences and molecular diagnostics executive with extensive commercialization ... inherited disease risk in future generations. In his new role, Matt will be ...
Breaking Biology Technology:
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
(Date:2/2/2017)... -- EyeLock LLC, a market leader of iris-based identity authentication ... You Should Know About Biometrics in the Cloud ."  ... a growing concern. In traditional schemes, cryptography is used ... schemes such as username/password suffer from inherent weaknesses. ... elegant solution to the problem of high-security user authentication. ...
(Date:2/1/2017)... IDTechEx Research, a leading provider of independent market research, business ... new report, Sensors for Robotics: Technologies, Markets and Forecasts 2017-2027 ... ... Revenues of ... for Robotics: Technologies, Markets and Forecasts 2017-2027: Machine vision, force sensing ...
Breaking Biology News(10 mins):